Philadelphia: Biotech Strategy Blog is in Philadelphia for the AACR-NCI-EORTC Molecular Targets  and Cancer Therapeutics Conference (aka known as ‘The Triple’) that starts today and goes on over the weekend until Monday.

Molecular Targets has always been one of my favourite meetings!

Coming here is a reminder that despite the excitement and promise of immunotherapy, there is a lot still happening in cancer research on targeted therapies, as well as the intersection of the two. I expect many of the thought leaders here to be talking about the challenge of how do we combine targeted therapy with immmunotherapy to best effect.

I don’t think there will be much on social media since much of the work discussed here is unpublished and we don’t tweet that, but if you do want to follow along, the Twitter hashtag is the memorable #Targets17. There’s also an app you can download to see the full program etc.

For BSB subscribers, over the weekend we’ll be providing a daily summary post at the end of each day on key topics, issues, and themes we’ve picked up during the meeting.

Today, there was a press conference at 9.15am with the three meeting co-chairs:

What did Drs Ribas, Gulley and Swanton have to say about what we can expect from the meeting and some of the key themes and noteworthy abstracts presented?

Stay tuned for more!

To learn more insights on this intriguing topic, subscribers can log-in or you can click to gain access to BSB Premium Content.

Posted by